Suppression of autophagy by BCR/ABL

Frontiers in Bioscience - Scholar

Volumn 4 S, Issue 2, 2012, Pages 453-460

  Calabretta, Bruno ^a   Salomoni, Paolo ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cell death; Leukemia; Oncogene; Review; Therapy

Indexed keywords

BCR ABL PROTEIN; CHLOROQUINE; IMATINIB; PROTEIN TYROSINE KINASE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADAPTATION; APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; GENE CONTROL; GENE REPRESSION; HUMAN; MACROAUTOPHAGY; NONHUMAN; ANIMAL; AUTOPHAGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; BENZAMIDES; CHLOROQUINE; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 84861734333     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s278     Document Type: Article

References (56)

1. H. Kantarjian, M. Keating, M Talpaz. RS Walters, T. Smith, A Cork. KB McCredie, EJ Freireich: Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 83, 445-454 (1987)
2. D. Savage, R. Szydlo, JM Goldman. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period: Br J Haematol 96, 111-116 (1997)
3. AS Spiers. Clinical manifestations of chronic granulocytic leukemia: Semin Oncol 22, 380-395 (1995)
4. Y Ben-Neriah. GQ Daley, A. Mes-Masson, O. Witte, D Baltimore. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene: Science 233, 212-214 (1986) (Pubitemid 16008117)
5. D Cortez. L Kadlec, AM Pendergast: Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol 15, 5531-5541 (1995)
6. A Goga. J McLaughlin, D. Afar, D. Saffran, ON Witte: Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 82, 981-988 (1995)
7. MY Gordon: Biological consequences of the BCR/ABL fusion gene in humans and mice. J Clin Pathol 52, 719-722 (1999) (Pubitemid 29481328)
8. RA Van Etten: Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J. Exp. Med. 204, 461-465 (2007) (Pubitemid 46457069)
9. C. Jamieson, L. Ailles, S. Dylla, M Muijtjens. C Jones, J. Zehnder, J Gotlib. K Li, M. Manz, A Keating. CL Sawyers, IL Weissman: Granulocyte- macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351, 657-667 (2004) (Pubitemid 39063268)
10. C Zhao. A Chen, C. Jamieson, M Fereshteh. A Abrahamsson, J Blum. HY Kwon, J Kim. JP Chute, D Rizzieri. M Munchhof, T Van Arsdale, T Reya: Hedgehog signaling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458, 776-779 (2009)
11. M Deininger. E Buchdunger, BJ Druker: The development of Imatinib as therapeutic agent for chronic myeloid leukemia. Blood 108, 2640-2649 (2005)
12. O. Ottmann, B. Druker, C. Sawyers, J. Goldman, J Reiffers. RT Silver, S Tura. T Fisher, M. Deininger, C. Schiffer, M Baccarani. A Gratwohl, A Hochhaus. D Hoelzer, S Fernandes-Reese. I Gathmann, R Capdeville, SG O'Brien: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100, 1965-1971 (2002) (Pubitemid 35001224)
13. C. Sawyers, A Hochhaus. E Feldman, J. Goldman, C. Miller, O. Ottmann, C. Schiffer, M Talpaz. F Guilhot, M. Deininger, T Fisher. SG O'Brien, R. Stone, C. Gambacorti-Passerini, N. Russel, J. Reiffers, T. Shea, B Chapuis. S Coutre, S Tura. E Morra, R. Larson, A Saven. C Peschel, A Gratwohl. F Mandelli, M Ben-Am. I Gathmann, R Capdeville. RL Paquette, BJ Druker: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99, 3530-3539 (2002) (Pubitemid 34534519)
14. W. Hofmann, L. Jones, N. Lemp, S d. Vos, H Gschaidmeier. D Hoelzer, O. Ottmann, HP Koeffler: Ph (+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99, 1860-1862 (2002) (Pubitemid 34533064)
15. S Branford. Z Rudzki, S Walsh. I Parkinson, A Grigg. J Szer, K Taylor. R Hermann, J. Seymour, C Arthur. D Joske, K Lynch, T Hughes: Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102, 276-283 (2003) (Pubitemid 36759665)
16. V Nardi. M Azam, GQ Daley: Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 11, 35-43 (2004) (Pubitemid 38021719)
17. S Soverini. G Martinelli, G Rosti. B Giannini, E Trabacchi. F Castagnetti, N Testoni. S Luatti, A d. vivo, D Cilloni. B Izzo, M Fava. E abruzzese, D Alberti. F Pane, G Saglio, M Baccarani: ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 23, 4100-4109 (2005) (Pubitemid 46211315)
18. S. Graham, H. Jorgensen, E Allan. C Pearson, M. Alcorn, L Richmond, TL Holyoake: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319-325 (2002)
19. N. Shah, C Tran. FY Lee, P Chen. D Norris, CL Sawyers: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401 (2004) (Pubitemid 38938156)
20. E Weisberg. PW Manley, W Breitenstein. J Bruggen, S. Cowan-Jacob, A Ray. B Huntly, D Fabbro. G Feudrich, E Hall-Meyers. AL Kung, J Mestan. GQ Daley, L Callahan. L Catley, C Cavazza. M Azam, D Neuberg. RD Wright, D. Gilliland, JD Griffin: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129-141 (2005) (Pubitemid 40248339)
21. T O'Hare. CA Eide, MW Deininger: Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110, 2242-2249 (2007) (Pubitemid 47523141)
22. T O. Hare, W. Shakespeare, X Zhu. CA Eide, V. Rivera, F Wang. LT Adrian, T Zhou. WS Huang, Q Wu. CA Metcalf, J. Tyner, M. Loriaux, A. Corbin, S Wardwell. Y Ning, J. Keats, Y Wang. R Sundaramoothi, M Thomas. D Zhou, J Snodgrass. L Commodore, T. Sayer, D. Dalgano, M. Deininger, B. Druker, T Clackson: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401-412 (2009)
23. X Jiang. Y Zhao, C Smith. M Gasparetto, A Turhan. A Eaves, C Eaves: Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21, 926-935 (2007) (Pubitemid 46672068)
24. M Copland. A Hamilton, L. Elrick, J. Baird, E. Allan, N Jordanides. M Barow, J. Mountford, TL Holyoake: Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107, 4532-453 (2006)
25. H. Jorgensen, E. Allan, N. Jordanides, J. Mountford, TL Holyoake: Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109, 4016-4019 (2007) (Pubitemid 46641755)
26. H Konig. M Holtz, H Modi. P Manley, T. Holyoake, S. Forman, R Bhatia: Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 22, 748-755 (2008) (Pubitemid 351552624)
27. H Konig. TL Holyoake, R Bhatia: Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 111, 2329-2338 (2008) (Pubitemid 351451441)
28. A Quintas-Cardama, J Cortes: Molecular biology of bcr/abl1-positive chronic myeloid leukemia. Blood 113, 1619-1630 (2009)
29. A. Corbin, A Agarwal. M Loriaux, J Cortes. MW Deininger, BJ Druker: Chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCRABL activity. J. Clin. Invest. December 13, 2010 (Epub ahead of print)
30. G Kroemer, M Jaattela: Lysosomes and autophagy in cell death control. Nat Rev Cancer 2005;5:886-897. (Pubitemid 41746033)
31. DJ Klionsky: Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 8, 931-937 (2007) (Pubitemid 47622558)
32. EH Baehrecke: Autophagy: dual roles in life and death? Nat Rev Mol Cell Biol 6, 505-510 (2005) (Pubitemid 40780562)
33. G Kroemer, B Levine: Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol 9, 1004-1010 (2008)
34. Y Kondo. T Kanzawa, R Sawaya, S Kondo: The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5, 726-734 (2005) (Pubitemid 41486365)
35. M. Maiuri, E Zalckvar. A Kimchi, G Kroemer: Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8, 741-752 (2007) (Pubitemid 47312826)
36. J. Lum, D. Bauer, M Kong. MH Harris, C Li. T Lindsten, CB Thompson: Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120, 237-248 (2005) (Pubitemid 40174766)
37. K. Maclean, F. Dorsey, J. Cleveland, MB Kastan: Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J. Clin Invest. 118, 79-88 (2008)
38. J. Lum, R. DeBerardinis, CB Thompson: Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 6, 439-448 (2005) (Pubitemid 40780556)
39. R. Amaravadi, D Yu. JJ Lum, T Bui. MA Christophorou, G. Evan, A Thomas-Tikhonenko, CB Thompson: Autophagy inhibition enhances therapyinduced apoptosis in a Myc-induced model of lymphoma. J. Clin. Invest. 117, 326-336 (2007) (Pubitemid 46203961)
40. M Degtyarev. A De Maziere, C Orr. J Lin, R. Lee, J. Tien, W. Prior, S va. Dijk, H Wu. DC Gray, D. Davis, H. Stern, L. Murray, K. Hoeflich, J Klumperman. LS Friedman, K Lin: Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J. Cell. Biol. 183, 101-116 (2008)
41. Q. Fan, C Cheng. C Hackett, M Feldmn. BT Houseman, T Nicolaides. D Haas-Kogan, C. Jones, S. Oakes, J Debnath. KM Schokat, WA Weiss: Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci. Signal. 3(147): ra81 (2010)
42. K Degenhardt. R Mathew, B Beaudoin. K Bray, D Anderson. G Chen, C Mukherjee. Y Shi, C Gelinas. Y Fan, D. Nelson, S Jin, E White: Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10, 51-64 (2006)
43. S Paglin. T Hollister, T Delohery. N Hackett, M McMahill. E Sphicas, D Domingo, J Yahalom: A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 61, 439-444 (2001) (Pubitemid 32128593)
44. H Ito. S Daido, T Kanzawa. S Kondo, Y Kondo: Radiation-induced autophagy is associated with LC3 and its inhibition sensitizes malignant glioma cells. Int J Oncol 26, 1401-1410 (2005)
45. M. Abedin, D Wang. MA McDonnell, U Lehmann, A Kelekar: Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ 14, 500-510 (2007)
46. T Kanzawa. IM Germano, T Komata. H Ito, Y Kondo, S Kondo: Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11, 448-457 (2004) (Pubitemid 38489422)
47. T Kanzawa. Y Kondo, H Ito. S Kondo, I Germano: Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 63, 2103-2108 (2003) (Pubitemid 36538613)
48. Z Lu. RZ Luo, Y Lu. X Zhandg, Q Yu. S Khare, S Kondo. Y Yu, G. Mills, WS-. Liao, RC Bast; The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J. Clin. Invest. 118, 3917-3929 (2008)
49. RK Amaravadi.: Autophagy-induced tumor dormancy in ovarian cancer. J. Clin. Invest. 118, 3837-3840 (2008)
50. A Colell. JE Ricci, S Tait. S Milasta, U Maurer. L Boucher-Hayes, P Fitzgerald. A Guio-Carrion, N. Waterhouse, C. Li, B Mari. P Barbry, D. Newmeyer, H. Beere, DR Green: GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell 129, 983-997 (2007) (Pubitemid 46813151)
51. I Dikic. T Johansen, T, V Kirkin: Selective autophagy in cancer development and therapy. Cancer Res. 70, 3431-3434 (2010)
52. B Calabretta, D Perrotti: The biology of CML blast crisis. Blood 103, 4010-4022 (2004) (Pubitemid 38685338)
53. S. Sharma, P Gajowniczek, IP Way: A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10, 425-435 (2006) (Pubitemid 44693471)
54. C Bellodi. MR Lidonnici, A Hamilton. A, G. Helgason, A. Soliera, M Ronchetti. S Galavotti, K. Young, T Selmi. R Yacobi, R. Van Etten, N Donato. A Hunter, D Dinsdale. E Tirro, P Vigneri. P Nicotera, M. Dyer, T Holyoake. P Salomoni, B Calabretta: Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J. Clin. Invest. 119, 1109-1123 (2009)
55. A Eisenberg-Lerner. S Bialik, A Kimchi: Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 16, 966-975 (2009)
56. Wullschleger S. Loewith R. Hall M.N. 2006 TOR signaling in growth and metabolism. Cell 124:3 471-484.